📋 Tender Overview
Waters Corporation unveiled new instruments software and product enhancements to drive drug discovery and development at the American Society for Mass Spectrometry ASMS 2022 Annual Conference. The products include the new Xevo G3 quadrupole time-of-flight QTof mass spectrometer CONFIRM Sequence - a new oligonucleotide sequencing confirmation app for the watersconnect software platform and an electrospray ionization source for the high-resolution Waters SELECT SERIES Multi-Reflecting Time of Flight MRT mass spectrometer.Innovation in mass spectrometry progresses rapidly. Our product introductions at this years ASMS benefit scientists throughout the drug development cycle said Jon Pratt Senior Vice President Waters Corporation. For researchers this means enhanced capability to answer fundamental scientific questions. For the analytical scientist compiling analytical data for new drug filings it means increased certainty and confidence in knowing precisely whats in their samples and in what quantities.Waters Xevo G3 QTof A Laboratory WorkhorseThe new Xevo G3 QTof system is a high-performance benchtop mass spectrometer for characterizing and quantifying molecules in applications such as biotherapeutics forensics metabolite identification metabolomics and extractables and leachables. The Xevo G3 QTof system is up to 10X more sensitive than its class-leading predecessor at transmitting thermally fragile molecules and excels at measuring and characterizing denatured or native proteins peptides and other biotherapeutics.Biopharmaceutical development and commercialization requires a deep understanding of product variation their degradation pathways and the processes that make them said Dr. Andrew Mahan Associate Director Mass Spectrometry Group Leader Cell Engineering and Early Development Janssen. The extended mass-to-charge ratio mz range of the Xevo G3 QTof is going to be ideal for the analysis of multi-specifics and for native MS analyses.Waters engineered the Xevo G3 QTof system to reliably give scientists both reproducible and accurate qualitative and quantitative information about molecules in their samples whether in very small or very large amounts.New Software App for Confirming Nucleic Acid Sequence of BiotherapeuticsThe CONFIRM Sequence app on the watersconnect software platform helps scientists using a Waters LC-MS System to confirm the nucleic acid sequence of therapeutics and identify impurities that could compromise product safety and efficacy.The CONFIRM Sequence app eliminates 50 of the time it takes for post-processing data review accelerating characterization and development of nucleic acid therapeutics.iiiThe new CONFIRM Sequence app is the first sequencing tool to integrate compliance-ready data acquisition processing and reporting - making it ideal for deployment in regulated development and Good Manufacturing Practice GMP labs.Coupling UPLC to Waters MRT SELECT SERIES Research Mass Spectrometer with ESI Source for Fast Molecular CharacterizationThe Waters SELECT SERIES MRT System is now compatible with UPLC-MS with an available electrospray ionization ESI source. Coupling the high resolution MRT System with the ESI source enables scientists to accurately resolve and measure low 200 ppb concentrations of sample analytes at UPLC acquisition speeds for metabolomics metabolite identification or peptide mapping applications.The superior performance of the SELECT SERIES MRT allows scientists to get the highest quality mass spectrometry data and information faster than any commercial mass spectrometer on the market today giving scientists a much clearer picture of the structure of their molecules at the isotope level iv.
